Bei Akademie registrieren
Sanofi S.A., FR0000120578

Sanofi expands antibody alliance: what it means for Sanofi stock

Published on 10/17/2026 at 10:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Sanofi expanded its Regeneron alliance on October 1. Sanofi stock has third-quarter results scheduled for October 30 and four antibody programs in the deal.

Upcoming corporate milestones

  • Sanofi and Regeneron announced an expanded alliance on October 1, 2026, including a USD 1.00 billion upfront payment and up to USD 7.00 billion in milestones.
  • The expanded agreement covers four long-acting antibody programs and a 50:50 split of future profits.
  • Sanofi's third-quarter 2026 results are scheduled for October 30, 2026.
Editorial photograph of financial trading monitors displaying pharmaceutical sector index charts and CAC 40 and EURONEXT tickers in a dark trading room with blue screen glow
Sanofi FR0000120578 editorial trading room screens showing pharma sector index and CAC 40 charts, Illustration mit AI erstellt.

Sanofi expanded its long-standing alliance with Regeneron on October 1, 2026, adding four next-generation, long-acting antibody programs. The companies said Regeneron will receive a USD 1.00 billion upfront payment and could receive up to an additional USD 7.00 billion in development, regulatory and commercial milestones, according to Sanofi.

Market context: Market report CAC 40.

The week in figures

The October 1 agreement covers REGN20423, a clinical-stage long-acting interleukin-13 antibody, a long-acting interleukin-4xinterleukin-13 bispecific antibody and two other preclinical antibodies. Sanofi said the companies will share development and commercialization costs and split future profits equally, as reported by Sanofi.

Weekend trading

Lang & Schwarz shows no current trading price for October 17, 2026. The next price is shown from the start of trading by the continuously updated real-time quote of Sanofi stock.

Dates of the coming week

Sanofi's third-quarter 2026 results are scheduled for October 30, 2026. The company announced the availability of its third-quarter aide-mémoire on October 6, 2026, stating that the document supports financial modeling and covers non-comparable items, foreign-currency impact and share count, according to Sanofi.

Disclaimer...
en | FR0000120578 | SANOFI S.A. | boerse | 70345806 | bgmi